DMAC - DiaMedica Therapeutics - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

DMAC is currently covered by 4 analysts with an average price target of $15.85. This is a potential upside of $10.7 (207.77%) from yesterday's end of day stock price of $5.15.

DiaMedica Therapeutics's activity chart (see below) currently has 13 price targets and 24 ratings on display. The stock rating distribution of DMAC is 100% BUY.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 9.52% with an average time for these price targets to be met of 131.43 days.

Highest price target for DMAC is $14, Lowest price target is $6, average price target is $10.

Most recent stock forecast was given by THOMAS FLATEN from LAKE STREET on 18-Jul-2025. First documented stock forecast 03-Jan-2019.

Currently out of the existing stock ratings of DMAC, 10 are a BUY (100%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$14

$9.82 (234.93%)

6 days ago
(18-Jul-2025)

0/3 (0%)

$9.82 (234.93%)

Buy

$12

$7.82 (187.08%)

$10

6 days ago
(18-Jul-2025)

0/5 (0%)

$7.82 (187.08%)

Buy

$6

$1.82 (43.54%)

$6

11 months 8 days ago
(16-Aug-2024)

2/4 (50%)

$2.4 (66.67%)

200

Buy

$8

$3.82 (91.39%)

$8

1 years 3 months ago
(24-Apr-2024)

1/6 (16.67%)

$5.55 (226.53%)

720

Buy

$11

$8.42 (326.36%)

$14

4 years 24 days ago
(30-Jun-2021)

0/2 (0%)

$6.82 (124.75%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is DMAC (DiaMedica Therapeutics) average time for price targets to be met?

On average it took 131.43 days on average for the stock forecasts to be realized with a an average price target met ratio 9.52

Which analyst has the current highest performing score on DMAC (DiaMedica Therapeutics) with a proven track record?

FRANCOIS BRISEBOIS

Which analyst has the current lower performing score on DMAC (DiaMedica Therapeutics) with a proven track record?

MATTHEW CAUFIELD

Which analyst has the most public recommendations on DMAC (DiaMedica Therapeutics)?

Francois Brisebois works at OPPENHEIMER and has 3 price targets and 2 ratings on DMAC

Which analyst is the currently most bullish on DMAC (DiaMedica Therapeutics)?

Etzer Darout with highest potential upside - $23.76

Which analyst is the currently most reserved on DMAC (DiaMedica Therapeutics)?

Elemer Piros with lowest potential downside - -$0

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?